Intellinetics Expands Payables Automation Solutions Practice with Leading Canadian Homebuilder
COLUMBUS, Ohio--(BUSINESS WIRE)--Intellinetics, Inc. (NYSE American: INLX), a digital transformation solutions provider, is pleased to announce that a leading Canadian-based homebuilder and land development company has signed a contract to implement its IntelliCloud™ Payables Automation System. The sale was driven by the new Automated Utility Invoice Coding module and represents $100K in Total Contract Value (TCV) with over $41K in annual SaaS revenue. The customer is scheduled to go live by July 31, 2025.
For homebuilders and other organizations that receive many utility invoices, general ledger coding and processing can be a major drain on time, energy, and resources. With high invoice volumes, complex allocations, manual data entry risks, and siloed information, the process is often inefficient and prone to errors like double payment. The Automated Utility Invoice Coding module, introduced to the market in March 2025, harnesses licensed AI-powered technology to revolutionize utility bill coding with low or no-touch processing. The module automatically identifies the lot number and determines its status (model, spec, or completed) and then assigns accurate coding for utilities like gas, electric, water, HOA, and property tax.
'We have had some great feedback since we introduced the Automated Utility Invoice Coding module during a webinar in March,' said James F. DeSocio, President & CEO at Intellinetics. 'In fact, another new customer told us they are already processing over 15,000 utility invoices a month through the system and over 80% are touchless! That's within 60 days of going live. Every month, the percentage of touchless invoices increases for the customer.'
'Despite the challenges affecting homebuilders, such as tariffs and interest, demand for our Payables Automation solutions continue to grow because our product saves them time and money,' said DeSocio. 'During times of economic uncertainty, investing in process efficiency becomes crucial because it strengthens a company's ability to adapt, reduce costs, and maintain profitability. By streamlining operations and identifying inefficiencies, businesses can become more agile and resilient, better positioning them for taking advantage in the upswing.'
Continued DeSocio, 'As reference accounts grow and share their story that our solutions are cost-effective with a tangible return on investment, particularly in a downturn, we remain confident in our payables automation solution for generating significant SaaS revenue growth.'
About Intellinetics, Inc.
Intellinetics, Inc. (NYSE American: INLX) is enabling the digital transformation. Intellinetics empowers organizations to manage, store and protect their important documents and data. Intellinetics' flagship solution, the IntelliCloud™ content management platform, delivers advanced security, compliance, workflow and collaboration features critical for highly regulated, risk-intensive markets. IntelliCloud connects documents to users and the processes they support anytime, anywhere to accelerate innovation and empower organizations to think and work in new ways. In addition, Intellinetics offers business process outsourcing (BPO), document and micrographics scanning services, and records storage. From highly regulated industries like Healthcare/Human Service Providers, K-12, Public Safety, and State and Local Governments, to businesses looking to move away from paper-based processes, Intellinetics is the all-in-one, compliant, document management solution. Intellinetics is headquartered in Columbus, Ohio. For additional information, please visit www.intellinetics.com
Cautionary Statement
Statements in this press release which are not purely historical, including statements regarding future business and growth, Total Contract Value of any customer contract, go-live dates for any customer software implementation, demand for our software products, the cost-effectiveness of our products for our customers, return on investment association with purchasing our software, and generation of significant SaaS revenue growth, execution of our business plan, strategy, direction and focus; and other intentions, beliefs, expectations, representations, projections, plans or strategies regarding future growth, financial results, and other future events are forward-looking statements. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that we cannot secure a renewal of our largest customer contract through their competitive bidding process that is currently open as of the date of this release, the risks associated with the effect of changing economic conditions including inflationary pressures, challenges with hiring and maintaining a stable workforce, our ability to execute on our business plan and strategy, trends in the products markets, variations in Intellinetics' cash flow or adequacy of capital resources, market acceptance risks, the success of Intellinetics' solutions providers, including human services, health care, and education, technical development risks, and other risks, uncertainties and other factors discussed from time to time in its reports filed with or furnished to the Securities and Exchange Commission, including in Intellinetics' most recent annual report on Form 10-K as well as subsequently filed reports on Form 8-K. Intellinetics cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Intellinetics disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release. Expanded and historical information is made available to the public by Intellinetics on its website at www.intellinetics.com or at www.sec.gov.
Non-GAAP Financial Measures
Intellinetics uses the metric of Total Contract Value as a key performance indicator that is not required by, or presented in accordance with, accounting principles generally accepted in the United States (GAAP). Total Contract Value does not have the effect of excluding, including, or adjusting an otherwise GAAP financial measure, and as such, is not a non-GAAP financial measure.
Total Contract Value: Estimated total future revenues from a particular contracted project. This refers to contracts or projects that have been awarded by our customers, and it presumes the provision of all software, subscription services, and/or professional services, with no termination of any awarded contracts. There can be no guarantee that all work will be completed during any fiscal period, or that the contracts will not be terminated before all the estimated future revenues are earned, received, and/or recognized. Total Contract Value is a performance measure that the Company believes provides useful information to its management and investors as it allows the Company to better track the Company's current sales performance, without any adjustment to exclude revenues that will not be earned, received, or recognized until future periods. Total Contract Value may refer to new sales in any of our revenue categories, including SaaS, perpetual software licenses, maintenance, storage and retrieval, and professional services, to new or existing customers. Total Contract Value is not a substitute for total revenue. There is no GAAP measure that is comparable to Total Contract Value, so the Company has not reconciled the Total Contract Value to any GAAP measure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
44 minutes ago
- Hamilton Spectator
Dreaming of a lakeside cottage but can't afford it? Co-ownership could open that door
A lakeview cottage with cosy rooms, a sandy beach nearby and a dock to gaze into the sunset was the dream for Corrine Evanoff. 'For years, I've been on this journey of trying to find a cottage that would work for us,' she said. But Evanoff and her husband didn't want to incur the burden of constant cottage maintenance — spending vacation days fixing decks and pruning trees. They opted instead to rent over the years, still hoping to one day buy. Then, it happened. They found a cottage not too far from home — for a fraction of the price they thought they'd have to pay, thanks to fractional ownership. Also called co-ownership, it allows people to buy a share of a property with others, whether it's family, friends or even strangers. Affordability sits at the heart of fractionally owned cottages. Many Canadians still find themselves priced out of the market, even as cottage prices have declined from peaks seen during the pandemic. Re/Max brokers and agents anticipate a national average price increase of about 1.8 per cent across the Canadian recreational market in 2025, a May report by the real estate firm, showed. On their first visit to check out a prospective cottage last fall, Evanoff recalled walking into a lake-facing cottage with large windows at Frontenac Shores in Cloyne, Ont., about 300 kilometres northeast of Toronto, and was sold. 'We sat in these Muskoka chairs on the beach and our feet are in the water, and I just felt the stress shredding off me,' she said. 'This is the dream that I've been dreaming for all these years … and this is within reach.' Evanoff and her husband now own one-tenth of a million-dollar cottage, costing them less than $100,000 for their share — and affording them five weeks a year at the property. Fractional ownership of a cottage is not like a timeshare, said Realtor Mike Lange, who has been dealing with co-owned cottages for about seven years in Kawartha Lakes, Ont. 'With a timeshare, you put your name in requesting a location, you have no guarantee that that's going to be available,' he said. 'There's been a lot of heartaches over them over the years.' Timeshare properties can be owned by for-profit corporations, leaving less autonomy for those staying there. Don Smith, who co-owns a property in Kawartha Lakes, bought into a cottage in the mid-2000s after he saw a newspaper ad about fractional cottage ownership. 'I was in the staff room reading the newspaper as a mathematics and computer studies teacher,' he recalled. 'As a math teacher, that caught my eye: What's this fraction all about, this cottage, this idea?' For the Smiths, fractional ownership wasn't a financial investment but a lifestyle investment that has paid off over the past two decades. 'This is where my daughter learned to swim, that's where my daughter learned to kayak, that is when my daughter had learned to appreciate animals.' But it may not be for everyone. Smith said fractionally owned cottages are usually 100 per cent debt-free. That means new co-owners typically can't secure a mortgage against the property from traditional banks and will have to rely on personal loans or a line of credit to buy their share. Personal touches to the cottage can also be missing with fractional ownership and people can't just show up at any time, he said. 'It's not like you can personally put all your favourite pictures and put all of the junk that you don't want in your home garage and take it up there and leave it,' Smith said. Real estate developer John Puffer has years of experience building cottages and selling them in fractional ownership arrangements in Ontario's cottage country regions. When he first got into the business, Puffer assumed the buyers would mostly be people in their 30s with young families. Instead, they happened to be people in their 50s and 60s, buying cottage shares for their adult children and grandchildren, or people who don't want to commit the dollars and worry about maintenance. 'That is part of the Canadian cottage experience in Ontario … that's where families congregate at the cottage and (it's) multi-generations,' said Puffer, president of Chandler Point Corp. Tanya Walker, litigation lawyer and managing partner at Walker Law, suggests potential buyers should get a good contract lawyer and treat the contract 'as if it's a pre-nuptial agreement' before signing on to be a co-owner. She said buyers going into fractional ownership should ask questions about who the other co-owners are, the voting rights people get for their share and what happens when they want to sell their stake. Walker added it's also important to look into who manages the property, the financials of the property as well as how much time you'll get to use the cottage and when. Puffer said people really have to understand what they're buying into. He suggested people read the contract and find out who's in control, what their obligations are, and talk to people who already own. For Evanoff and her husband, it will be their third time heading up to the Frontenac Shores cottage next month. 'It's like, wow! That just seems like a gift,' she said. 'This (fractional ownership) seems like the best-kept secret but I think it's going to catch on ... and you're going to see a lot of people tap into this market.' This report by The Canadian Press was first published June 15, 2025.
Boston Globe
4 hours ago
- Boston Globe
Logan Airport is starting to see decline in Canadian travelers
The drop in April marked the first year-over-year decline in Canadian visitors at the airport in 2025; the total is still up slightly for the year so far, when compared to the first four months of 2024. (May passenger traffic numbers are not yet public.) Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'That's obviously incredibly disappointing [but] with one month of data, I'm not ready to press the panic button,' Davey said in an interview earlier this month, after Massport published the April numbers. Advertisement National statistics released by the Canadian government last week indicate the trend most likely continued at Logan through May. Plane trips by Canadian residents from the US fell 24 percent in May, year over year, while Canadian vehicular trips from the US fell 38 percent. The backlash in Canada started early this year. Then-Prime Minister Justin Trudeau urged Canadians to vacation in their home country instead of going to the US, as President Trump imposed new tariffs on goods imported from Canada and talked repeatedly about the benefits of Canada becoming the '51st state.' Advertisement Current prime minister Mark Carney has strongly rebuffed the 51st state idea, though he indicated several days ago that he's hopeful about progress with the Trump administration on trade issues. In an attempt to counteract some of the Trump administration's hostility, Governor Maura Healey on Monday will be hosting in Boston several Canadian premiers and governors from Northeast states to talk about ways to maintain strong economic relations among the states and provinces. Much is at stake: Visiting Canadians spent an estimated $20 billion in the US last year. Amid the pushback in Canada to US leisure travel, JetBlue decided to cancel a new flight from Boston to Halifax it had planned, and Porter Airlines cut one of its Boston flights to Ottawa. Travel research firm Tourism Economics is predicting much bigger drops ahead for Greater Boston, with 657,000 Canadian visits expected to the region in 2025, a 20 percent decline from 2024, and a 24 percent drop from what was originally projected for 2025. David O'Donnell, a vice president with the Meet Boston tourism bureau, said his organization hasn't yet heard from local hotels about Canadian travel, but it expects a decline in international travelers to pick up in the summer. Many visitors who booked in the first half of the year would have faced cancellation fees if they opted not to come, but in the second half of the year, many of the bookings will reflect decisions made since Trump took office. Concerns about Canadian tourism prompted state Senator John Keenan of Quincy to file a budget amendment last month requiring the Massachusetts Office of Travel and Tourism to report to the Legislature the feasibility of promoting Massachusetts as a destination for residents of countries showing a decline in travel to this state in 2025. The Senate adopted the language as part of its state budget proposal, but its fate now remains tied to House-Senate budget negotiations. Advertisement 'Clearly our Canadian numbers, like those at a lot of other [US] airports, are going in the wrong direction,' Davey said. 'I hope it's not a canary in the coal mine for us, but we're going to keep a close eye on it.' Jon Chesto can be reached at
Business Wire
7 hours ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine
